Bird & Bird advises AddLife on the acquisition of Ropox A/S

The Swedish listed company AddLife AB is a market leading player within Life Science offering quality products and advice to both the private and the public sectors, primarily in the Nordics and the rest of Europe.


 

The Swedish listed company AddLife AB is a market leading player within Life Science offering quality products and advice to both the private and the public sectors, primarily in the Nordics and the rest of Europe.

Bird & Bird has advised AddLife on the acquisition of Ropox A/S, a market leader among the world’s leading specialists within the production of assistive devices and furniture for disabled persons and equipment for rehabilitation by means of occupational therapy and physiotherapy. The Ropox premises are located in Næstved with 73 employees and an annual turnover of approximately DKK 65 million.

AddLife has purchased all the shares with effect from 1 October 2020. The purchase price is confidential.

AddLife’s press release on the acquisition can be found here.

AddLife was advised by senior counsel Mogens Dyhr Vestergaard, senior associate Ted Rosenbaum and junior associate Filip Kaas.

Latest insights

More Insights
featured image

Women in Tech: At the forefront of innovation - Key takeaways from Dana Ghosn, Typeless

3 minutes Aug 07 2025

Read More
featured image

German Constitutional Court upholds pharmaceutical cost control measures: implications for drug pricing and reimbursement

5 minutes Aug 05 2025

Read More
featured image

The FCAs new Public Offers and Admissions to trading regime

5 minutes Aug 04 2025

Read More